Testing effectiveness (Phase 2)UnknownNCT04626908
What this trial is testing
Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma
Who this might be right for
Relapsed and RefractoryLymphoid Hematological Malignancies
He Huang 18